Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt

Ependymoma: early-phase trial registry

7 of 21 indexed Ependymoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #797 of 28,707 conditions by registered trial count.

21 US clinical trials · 7 currently recruiting · #797 of 28,707 conditions by registered trial count

Ependymoma: 21 US clinical trials tracked, 7 recruiting.

Ependymoma is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 4 of these trials.

Enrollment posture brief

Registry condition ependymoma

OPEN 7 | RECR 33% | LATE 1 | EARLY 18 | RANK #797 | SPON 4

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Anal Cancer42.9%Ependymoma (this)33%Allergic Conjunctivitis14.3%Attention Deficit Disorder W4.8%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Ependymoma

Ependymoma lists 7 open slots (33% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ependymoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ependymoma is recruiting below its size-band peers.

    7 of 21 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Ependymoma research.

    Children's Oncology Group accounts for 4 of 21 trials (19%). 14 distinct sponsors appear on at least one study for this condition label.

  3. Most Ependymoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 62 among the 21 trials that report a genuine target (sentinel values excluded). 16 of those (76.2%) plan for fewer than 100 participants.

  4. Ependymoma research is mostly interventional.

    21 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 114Phase 24Phase 31

Open and recent trials

21 total, page 1 of 1

RECRUITING Phase 1 146 participants

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

National Cancer Institute (NCI)

NCT06161519

RECRUITING Phase 1 90 participants

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Seattle Children's Hospital

NCT04185038

RECRUITING NA 74 participants

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

University of California, San Francisco

NCT05057702

RECRUITING Phase 1 48 participants

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

St. Jude Children's Research Hospital

NCT05835687

RECRUITING Phase 1 48 participants

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

M.D. Anderson Cancer Center

NCT03750513

RECRUITING Phase 1 37 participants

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Theodore S. Johnson

NCT05106296

RECRUITING Phase 1 12 participants

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

Children's National Research Institute

NCT06193759

ACTIVE NOT RECRUITING Phase 2 503 participants

Methionine PET/CT Studies In Patients With Cancer

St. Jude Children's Research Hospital

NCT00840047

ACTIVE NOT RECRUITING Phase 3 479 participants

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Children's Oncology Group

NCT01096368

ACTIVE NOT RECRUITING Phase 2 130 participants

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Theodore S. Johnson

NCT04049669

ACTIVE NOT RECRUITING Phase 2 100 participants

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Scott R. Plotkin, MD, PhD

NCT04374305

ACTIVE NOT RECRUITING Phase 1 83 participants

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

GlaxoSmithKline

NCT06521567

ACTIVE NOT RECRUITING NA 80 participants

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

Children's Oncology Group

NCT03033992

ACTIVE NOT RECRUITING Phase 2 68 participants

A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma

St. Jude Children's Research Hospital

NCT02125786

ACTIVE NOT RECRUITING Phase 1 62 participants

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

Dana-Farber Cancer Institute

NCT03152318

ACTIVE NOT RECRUITING Phase 1 50 participants

HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

Children's Oncology Group

NCT04903080

ACTIVE NOT RECRUITING Phase 1 35 participants

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Children's Oncology Group

NCT04978727

ACTIVE NOT RECRUITING Phase 1 12 participants

Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

University of Florida

NCT07031765

ACTIVE NOT RECRUITING Phase 1 10 participants

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Seattle Children's Hospital

NCT03500991

ACTIVE NOT RECRUITING Phase 1 10 participants

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

City of Hope Medical Center

NCT04661384

COMPLETED Phase 1 18 participants

Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors

Emory University

NCT01331135

Phase Distribution

PhaseTrial count
Phase 1 14
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Ependymoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cyclophosphamide Drug
4 trials
Indoximod Drug
2 trials
HER2 Specific CAR T Cell Biological
1 trials
Cobolimab Drug
1 trials
Resection or biopsy Procedure
1 trials
exHSC Biological
1 trials
Stereotactic biopsy Procedure
1 trials
rQNestin Drug
1 trials

US sites by state

Facility locations filed on Ependymoma trials. A trial with sites in several states counts in each.

California 8 trials
Texas 6 trials
New York 6 trials
Georgia 6 trials
Ohio 5 trials
Massachusetts 5 trials
Tennessee 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ependymoma page

21 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ependymoma condition card totals 21 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.